{"id":"aliskiren-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"8df0ca6a-58cf-41fc-b890-5c7fa5a3792c","title":"TEKTURNA HCT (ALISKIREN HEMIFUMARATE AND HYDROCHLOROTHIAZIDE) TABLET, FILM COATED [NODEN PHARMA USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aliskiren directly inhibits renin, the first enzyme in the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensinogen to angiotensin I and thereby reducing angiotensin II formation. Hydrochlorothiazide is a thiazide diuretic that promotes sodium and water excretion, reducing blood volume and peripheral vascular resistance. Together, these complementary mechanisms provide additive antihypertensive effects.","oneSentence":"Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:59.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT00667719","phase":"PHASE3","title":"A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06-05","conditions":"Essential Hypertension","enrollment":564},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00765947","phase":"PHASE4","title":"Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Essential Hypertension ( Mild to Moderate)","enrollment":256},{"nctId":"NCT01519635","phase":"PHASE4","title":"Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2011-10","conditions":"Hypertension","enrollment":24},{"nctId":"NCT00219102","phase":"PHASE3","title":"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension, Diabetes","enrollment":336},{"nctId":"NCT01103245","phase":"PHASE1","title":"Aldosterone and the Metabolic Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-03","conditions":"Metabolic Diseases, Diabetes Mellitus, Endocrine System Diseases","enrollment":69},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT00994253","phase":"PHASE4","title":"Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2009-08","conditions":"Hypertension, Diabetes Type 2","enrollment":""},{"nctId":"NCT03115853","phase":"PHASE4","title":"The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-06","conditions":"High Blood Pressure","enrollment":31},{"nctId":"NCT00219024","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-08","conditions":"Hypertension","enrollment":2775},{"nctId":"NCT00219063","phase":"PHASE3","title":"A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":"Hypertension","enrollment":844},{"nctId":"NCT01056731","phase":"PHASE4","title":"A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"High Blood Pressure","enrollment":253},{"nctId":"NCT01070030","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Stage II Hypertension","enrollment":230},{"nctId":"NCT00386139","phase":"PHASE3","title":"A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-09","conditions":"Hypertension","enrollment":881},{"nctId":"NCT00387517","phase":"PHASE3","title":"Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":726},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT00171405","phase":"PHASE3","title":"A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension","enrollment":250},{"nctId":"NCT00787605","phase":"PHASE4","title":"Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension, Diabetes Mellitus","enrollment":860},{"nctId":"NCT00739596","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Hypertension","enrollment":332},{"nctId":"NCT01480791","phase":"PHASE2","title":"Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":""},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01425242","phase":"NA","title":"Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Hypertension, Abdominal Aortic Aneurysm","enrollment":3},{"nctId":"NCT01176032","phase":"PHASE4","title":"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension, Left Ventricle Hypertrophy","enrollment":74},{"nctId":"NCT01259297","phase":"PHASE3","title":"A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Cardiovascular Events","enrollment":2336},{"nctId":"NCT00386607","phase":"PHASE3","title":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":601},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT01302899","phase":"PHASE2","title":"To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Non-diabetic Nephropathy","enrollment":8},{"nctId":"NCT01138423","phase":"PHASE4","title":"Treatment of Adiposity Related hypErTension (TARGET)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2010-08","conditions":"Hypertension, Abdominal Obesity, Metabolic Syndrome","enrollment":32},{"nctId":"NCT00219037","phase":"PHASE3","title":"Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-06","conditions":"Hypertension","enrollment":1955},{"nctId":"NCT00294710","phase":"PHASE3","title":"A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":"Hypertension","enrollment":976},{"nctId":"NCT00797862","phase":"PHASE3","title":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":1254},{"nctId":"NCT00942994","phase":"PHASE4","title":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Hypertension","enrollment":412},{"nctId":"NCT00705575","phase":"PHASE3","title":"Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06","conditions":"Hypertension","enrollment":688},{"nctId":"NCT00765674","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":1191},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00760266","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":451},{"nctId":"NCT00368277","phase":"PHASE3","title":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Hypertension","enrollment":901},{"nctId":"NCT00772577","phase":"PHASE4","title":"Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Hypertension","enrollment":386},{"nctId":"NCT00797316","phase":"PHASE4","title":"Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":532},{"nctId":"NCT00402103","phase":"PHASE3","title":"An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Hypertension","enrollment":556}],"_emaApprovals":[],"_faersSignals":[{"count":17,"reaction":"DEMENTIA"},{"count":17,"reaction":"DIZZINESS"},{"count":17,"reaction":"HAEMATOCHEZIA"},{"count":5,"reaction":"HEADACHE"},{"count":4,"reaction":"BLOOD PRESSURE INCREASED"},{"count":4,"reaction":"FATIGUE"},{"count":4,"reaction":"NAUSEA"},{"count":3,"reaction":"COUGH"},{"count":3,"reaction":"CYSTITIS"},{"count":3,"reaction":"MALAISE"}],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aliskiren Hydrochlorothiazide","genericName":"Aliskiren Hydrochlorothiazide","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}